Mahathir Bayena

A White House meeting involving administration officials, lawmakers and law enforcement organisations has highlighted a potential path forward for the CLARITY Act as supporters seek a Senate vote before the August recess.

Crypto prediction markets have surpassed $2 billion in bets on the winner of the 2026 FIFA World Cup, making it the largest single prediction market event in the industry's history.

Vitrafy Life Sciences (ASX:VFY) secured $30 million through a non-underwritten institutional placement for its international expansion.

Neurizon Therapeutics (ASX:NUZ) announced that its HEALEY ALS Platform Trial has surpassed the critical 50% dosing milestone.

Digital Asset has raised $355 million in a funding round led by Andreessen Horowitz's crypto arm, strengthening its position as a key provider of blockchain infrastructure for traditional financial institutions.

BHP (ASX:BHP) faces major disruptions as AMWU and ETU members vote for protected strike action at Port Hedland over an ongoing pay dispute.

Genmab (NASDAQ:GMAB) announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, which evaluates the subcutaneous T-cell engaging bispecific antibody epcoritamab in combination with rituximab and lenalidomide (epcoritamab plus R2).

Climb Bio (NASDAQ:CLYM) reported positive initial Phase 1b clinical data for its drug candidate budoprutug, an anti-CD19 monoclonal antibody, which is being developed to treat adults with primary immune thrombocytopenia.

Nurix Therapeutics (NASDAQ:NRIX) released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, demonstrating sustained efficacy and high response rates across multiple lines of therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The board of directors of Target (NYSE:TGT) declared a quarterly cash dividend of $1.16 per common share, representing a 1.8% increase over its previous distribution baseline.